Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ: ELDN) will release its third-quarter financial results for the period ended September 30, 2022, on November 14, 2022, after market close. A conference call and webcast to discuss these results will take place at 4:30 PM ET on the same day. Eledon focuses on developing treatments targeting the CD40L pathway, with its lead candidate being tegoprubart, intended for organ transplant recipients, autoimmune disease patients, and those with ALS. The event will be archived on the company's website for one year.

Positive

• Eledon is developing tegoprubart, a high-affinity anti-CD40L antibody with broad therapeutic potential.
• The upcoming financial results release and conference call may provide insights into the company's progress.

Negative

• None.

Management to host conference call and webcast at 4:30 pm ET

IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it plans to release financial results for the third quarter ended September 30, 2022 on Monday, November 14, after the close of trading. Eledon’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.

Conference Call and Webcast Details:

Monday, November 14, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time
Toll Free: 877-300-8521
International: 412-317-6026
Conference ID: 10171988
Webcast: https://ir.eledon.com/events-and-presentations/events

After the live webcast, the event will be archived on Eledon’s website for one year.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

FAQ

When will Eledon Pharmaceuticals release its third-quarter financial results for 2022?

Eledon Pharmaceuticals plans to release its third-quarter financial results on November 14, 2022.

What time is Eledon Pharmaceuticals' conference call scheduled for?

The conference call for Eledon Pharmaceuticals is scheduled for November 14, 2022, at 4:30 PM ET.

What is the focus of Eledon Pharmaceuticals' lead compound tegoprubart?

Tegoprubart is focused on treating individuals requiring organ transplants, living with autoimmune diseases, or affected by ALS.

How can I access the Eledon Pharmaceuticals conference call webcast?

The conference call webcast can be accessed via Eledon's website and will be archived for one year after the live event.